Company Overview - Corpay, Inc. is a global commercial payments solution provider based in Peachtree Corners, GA, helping companies automate, secure, digitize, and control payments for employees and suppliers [11] - The company serves businesses, partners, and merchants across North America, Latin America, Europe, and the Asia Pacific [11] Investment Ratings - Corpay has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a moderate investment outlook [11] - The Value Style Score for Corpay is also rated B, supported by a forward P/E ratio of 14.04, which is attractive for value investors [12] Earnings Estimates - In the last 60 days, three analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.40 to $25.22 per share [12] - Corpay has an average earnings surprise of +0.8%, suggesting a positive trend in earnings performance [12] Investment Considerations - With a solid Zacks Rank and strong Value and VGM Style Scores, Corpay is recommended for investors' consideration [12]

Company Overview - ALX Oncology Holdings Inc. (ALXO) is part of the Medical sector, which includes 928 individual stocks and holds a Zacks Sector Rank of 10 [2] - ALX Oncology is currently rated with a Zacks Rank of 2 (Buy), indicating a positive earnings outlook [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for ALXO's full-year earnings has increased by 16.9%, reflecting improved analyst sentiment [4] - ALXO has returned approximately 81.4% year-to-date, significantly outperforming the average gain of 5.3% for Medical stocks [4] - In the Medical - Biomedical and Genetics industry, which includes 449 companies, ALXO is performing better than the average industry gain of 23.6% this year [6] Comparative Analysis - Another Medical stock, Amneal Pharmaceuticals (AMRX), has returned 15.2% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Amneal Pharmaceuticals belongs to the Medical - Drugs industry, which has a lower year-to-date gain of +2.7% and is ranked 146 [7]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks likely to outperform the market in the short term [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score identifies attractive stocks based on valuation ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors [3] Growth Score - The Growth Style Score focuses on a company's future prospects and financial health, analyzing projected and historical earnings, sales, and cash flow to find sustainable growth stocks [4] Momentum Score - The Momentum Style Score helps investors capitalize on price trends, using metrics like one-week price changes and monthly earnings estimate changes to identify optimal entry points [5] VGM Score - The VGM Score combines the three Style Scores, providing a comprehensive rating that highlights stocks with strong value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.83% since 1988, outperforming the S&P 500 [7][8] - There are typically over 800 top-rated stocks available, making it essential for investors to utilize Style Scores for better selection [9] Stock to Watch: Incyte Corporation - Incyte Corporation, a biopharmaceutical company, is currently rated 3 (Hold) on the Zacks Rank and has a VGM Score of A, indicating solid potential [12] - The company has a Value Style Score of B, supported by a forward P/E ratio of 14, making it attractive to value investors [13] - Recent analyst revisions have increased earnings estimates for fiscal 2025, with the Zacks Consensus Estimate rising to $6.87 per share and an average earnings surprise of +14.4%, positioning Incyte as a noteworthy investment opportunity [13]

Core Viewpoint - Castle Biosciences, Inc. (CSTL) has experienced significant selling pressure, resulting in a 16.8% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if CSTL is oversold, with a current RSI reading of 25.01 indicating potential for a trend reversal [2][5] - Stocks oscillate between overbought and oversold conditions, and the RSI helps identify when a stock's price may be due for a reversal, suggesting that CSTL may present an entry opportunity for investors [3] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for CSTL by 13.5% over the last 30 days, indicating a strong consensus among sell-side analysts that could lead to price appreciation [7] - CSTL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which further supports the potential for a turnaround in the near term [8]

Core Viewpoint - S&P Global (SPGI) has experienced a significant decline of 18.9% over the past four weeks, but it is now in oversold territory, indicating a potential for a trend reversal supported by analyst consensus for better-than-expected earnings [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is a momentum oscillator that helps identify whether a stock is oversold, with readings below 30 typically indicating oversold conditions [2]. - SPGI's current RSI reading is 18.55, suggesting that the heavy selling pressure may be exhausting, which could lead to a price rebound as the stock seeks to return to its previous equilibrium [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts that earnings estimates for SPGI have increased by 0.3% over the last 30 days, indicating a positive trend that often correlates with price appreciation [7]. - SPGI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8].

Core Viewpoint - Ford is expected to report its fourth-quarter 2025 results, with an EPS estimate of 17 cents and automotive revenues of $41.2 billion, reflecting a year-over-year decline in both metrics [1][2]. Earnings Estimates - The EPS estimate for the upcoming quarter has increased by 10 cents over the past month, but it still represents a 56% decline year-over-year. Revenue estimates indicate an 8% decrease compared to the same quarter last year [2]. - For the full year 2025, automotive revenues are projected at $173 billion, showing a modest 1% increase year-over-year, while the EPS consensus indicates a 39% contraction. However, the EPS for 2026 is expected to grow by 35.2% from 2025 levels [3]. Performance Indicators - Ford has consistently surpassed earnings estimates in the past four quarters, and current indicators suggest a strong likelihood of an earnings beat this time, supported by an Earnings ESP of +16.06% and a Zacks Rank of 1 [4]. - The most accurate EPS estimate for the current quarter is 19 cents, while the Zacks Consensus Estimate is 17 cents [5]. Sales and Market Dynamics - Ford's overall sales rose by 2.7% in Q4 2025, totaling over 545,200 vehicles, with hybrid sales increasing by 17.6% year-over-year [8]. - The company faces challenges in its EV segment, with a significant drop in EV sales exceeding 50% due to the withdrawal of the federal EV tax credit, particularly affecting F-150 Lightning volumes [6][7]. Strategic Initiatives - Ford anticipates $19.5 billion in special charges related to restructuring its U.S. EV strategy, with $5.5 billion impacting cash flows through 2026 and 2027 [7]. - The Ford Pro unit is expected to contribute positively, with projected revenues of approximately $15 billion and EBIT of $1.4 billion, driven by rising paid software subscriptions [9]. Market Position and Valuation - Over the past six months, Ford's shares have increased by 24%, outperforming the industry and Tesla, while underperforming General Motors [10]. - The company is currently trading at a forward sales multiple of 0.32, indicating it may be undervalued compared to the industry [13]. Future Growth Prospects - Ford is shifting its focus towards hybrids and gas-powered vehicles in response to slowing EV adoption, which is expected to help maintain margins and volume [15]. - The company is also exploring future growth avenues, including a battery energy storage systems business and advancements in autonomous driving technology [18].

Core Insights - Antero Midstream Corporation (AM) is scheduled to report its fourth-quarter 2025 results on February 11, after market close [1] - In the last reported quarter, AM's adjusted earnings of 24 cents per share fell short of the Zacks Consensus Estimate of 25 cents due to increased operating expenses, although higher gathering and compression volumes helped mitigate the impact [1] Earnings Performance - AM has beaten earnings estimates in two of the last four quarters, missed in one, and reported breakeven in another, resulting in an average earnings surprise of 3.26% [2] - The Zacks Consensus Estimate for fourth-quarter earnings per share remains at 24 cents, reflecting no revisions in the past week, which indicates a 4.4% improvement from the same quarter last year [3] Revenue Expectations - The Zacks Consensus Estimate for revenues in the fourth quarter is projected at $293.9 million, representing a 2.2% increase from the year-ago figure [3][8] - AM is expected to generate revenue from stable, fee-based contracts primarily with Antero Resources Corporation for the transportation and processing of natural gas and liquefied petroleum gas [4] Earnings Prediction - The earnings model suggests a potential earnings beat for AM, supported by a positive Earnings ESP of +0.84% and a Zacks Rank of 3 (Hold) [5] - The company is anticipated to report revenues from its pipeline, gathering, compression, processing, and water services assets [8]

Core Viewpoint - Arrow Electronics has shown strong stock performance, with a 37.9% increase over the past month and a 44% gain since the beginning of the year, outperforming both the Zacks Computer and Technology sector and the Zacks Electronics - Parts Distribution industry [1] Financial Performance - The company has consistently exceeded earnings expectations, reporting an EPS of $4.39 against a consensus estimate of $3.55 in its last earnings report [2] - For the current fiscal year, Arrow Electronics is projected to achieve earnings of $11.94 per share on revenues of $31.53 billion, reflecting an 8.44% increase in EPS and a 2.2% increase in revenues [3] Valuation Metrics - Arrow Electronics trades at a valuation of 13.3 times the current fiscal year EPS estimates, below the peer industry average of 17.3 times [7] - The stock's trailing cash flow valuation is at 11 times, compared to the peer group's average of 15.4 times, and it has a PEG ratio of 1.24, indicating strong value potential [7] Style Scores and Zacks Rank - The company holds a Value Score of A, with Growth and Momentum Scores of B, resulting in a combined VGM Score of A, making it attractive for value investors [6][9] - Arrow Electronics has a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [8]

Company Performance - Carpenter Technology (CRS) shares have increased by 11.1% over the past month, reaching a new 52-week high of $370.59 [1] - Year-to-date, Carpenter has gained 16%, compared to 16.3% for the Zacks Basic Materials sector and 18.3% for the Zacks Steel - Specialty industry [1] Earnings and Revenue Expectations - Carpenter has consistently beaten earnings estimates, reporting EPS of $2.33 against a consensus estimate of $2.2 in its last earnings report [2] - For the current fiscal year, Carpenter is expected to post earnings of $10.2 per share on revenues of $3.07 billion, reflecting a 36.5% increase in EPS and a 6.59% increase in revenues [3] - For the next fiscal year, expected earnings are $12.13 per share on revenues of $3.37 billion, indicating year-over-year changes of 18.81% in EPS and 9.93% in revenues [3] Valuation Metrics - Carpenter's stock trades at 35.8 times current fiscal year EPS estimates, which is above the peer industry average of 19.1 times [7] - On a trailing cash flow basis, Carpenter trades at 35.1 times compared to the peer group's average of 13.8 times [7] - The stock has a PEG ratio of 1.44, which does not place it among the top echelon of stocks from a value perspective [7] Zacks Rank and Style Scores - Carpenter currently holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts [8] - The company has a Value Score of F, while its Growth and Momentum Scores are A and B, respectively, resulting in a VGM Score of B [6] Industry Comparison - Insteel Industries, Inc. (IIIN), a peer in the industry, also has a Zacks Rank of 2 (Buy) and shows strong earnings performance, beating consensus estimates by 18.18% [10][11] - IIIN is expected to post earnings of $3.04 per share on revenues of $741 million for the current fiscal year, with shares gaining 10.4% over the past month [11] - The Steel - Specialty industry ranks in the bottom 69% of all industries, but there are positive tailwinds for both CRS and IIIN [12]

Core Insights - Crocs, Inc. (CROX) is expected to report fourth-quarter 2025 results on February 12, with revenue estimates at $916.6 million, reflecting a 7.4% decline year-over-year. Earnings per share are estimated at $1.91, indicating a 24.2% decrease from the previous year [1][3]. Financial Performance - The company has a trailing four-quarter earnings surprise average of 14.3%, with the last quarter's earnings exceeding estimates by 22.2% [2]. - Management projected a revenue decline of approximately 8% year-over-year, with Crocs brand revenues expected to drop around 3% and HEYDUDE brand revenues anticipated to fall mid-20% [5]. Operational Challenges - Crocs is facing a challenging operating environment, with margins pressured by increased expenses, tariffs, and higher selling, general and administrative (SG&A) costs [3][9]. - The HEYDUDE brand has been experiencing weak trends, with revenue estimates for the quarter at $175 million, down about 23% year-over-year due to cautious consumer behavior and wholesale channel pressures [4][9]. Brand Performance - Despite challenges, Crocs has seen strength in its core products, including clogs, sandals, and personalization offerings, which may help cushion overall performance [6][9]. - The Jibbitz business has also shown encouraging results, contributing positively to the company's performance [6]. Valuation - Crocs is currently trading at a forward 12-month price-to-earnings ratio of 6.83x, significantly below its five-year high of 25.08x and the industry average of 16.16x, indicating an attractive investment opportunity [10]. - The company's shares have increased by 12.1% over the past six months, contrasting with a 2.7% decline in the industry [10].